Stephen M. Stahl, M.D., PhD, Dsc (Hon.) is an Adjunct Professor of Psychiatry at the University of California San Diego, Honorary Visiting Senior Fellow at the University of Cambridge, UK and Director of Psychopharmacology for California Department of State Hospitals. Over the past 36 months (January 2016 - December 2018) Dr. Stahl has served as a consultant to Acadia, Adamas, Alkermes, Allergan, Arbor Pharmaceutcials, AstraZeneca, Avanir, Axovant, Axsome, Biogen, Biomarin, Biopharma, Celgene, Concert, ClearView, DepoMed, Dey, EnVivo, EMD Serono, Ferring, Forest, Forum, Genomind, Innovative Science Solutions, Intra-Cellular Therapies, Janssen, Jazz, Lilly, Lundbeck, Merck, Neos, Novartis, Noveida, Orexigen, Otsuka, PamLabs, Perrigo, Pfizer, Pierre Fabre, Reviva, Servier, Shire, Sprout, Sunovion, Taisho, Takeda, Taliaz, Teva, Tonix, Trius, Vanda, Vertex and Viforpharma; he has been a board member of RCT Logic and Genomind; he has served on speakers bureaus for Acadia, Astra Zeneca, Dey Pharma, EnVivo, Eli Lilly, Forum, Genentech, Janssen, Lundbeck, Merck, Otsuka, PamLabs, Pfizer Israel, Servier, Sunovion and Takeda and he has received research and/or grant support from Acadia, Alkermes, AssureX, Astra Zeneca, Arbor Pharmaceuticals, Avanir, Axovant, Biogen, Braeburn Pharmaceuticals, BristolMyer Squibb, Celgene, CeNeRx, Cephalon, Dey, Eli Lilly, EnVivo, Forest, Forum, GenOmind, Glaxo Smith Kline, Intra-Cellular Therapies, ISSWSH, Janssen, JayMac, Jazz, Lundbeck, Merck, Mylan, Neurocrine, Neuronetics, Novartis, Otsuka, PamLabs, Pfizer, Reviva, Roche, Sepracor, Servier, Shire, Sprout, Sunovion, TMS NeuroHealth Centers, Takeda, Teva, Tonix, Vanda, Valeant and Wyeth.

References

1. Stahl , SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications . 4th ed . New York, NY : Cambridge University Press ; 2013 .

2. NUEDEXTA® Prescribing Information . Aliso Viejo, CA: Avanir Pharmaceuticals, Inc.; January 2019 .

3. WELLBUTRIN® Prescribing Information . Research Triangle Park, NC: GlaxoSmithKline; August 2017 .

4. O’Gorman , C , Iosifescu , DV , Jones , A , et al . Clinical development of AXS-05 for treatment resistant depression and agitation associated with Alzheimer’s disease. P7 – 122 . Presented at the APA Annual Meeting 2018; May 5-9, 2018 ; New York, NY.

5. Crupi , R , Marino , A , and Cuzzocrea , S. New Therapeutic Strategy for Mood Disorders . Curr Med Chem . 2011 ; 18 ( 28 ): 4284 –98.

6. Sen , S , Duman , R , and Sanacora , G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: Meta-analyses and implications . Biol Psychiatry 2008 ; 64 : 527 – 532 .

7. Deyama , S , Bang , E , Wohleb , ES , et al . Role of neuronal VEGF signaling in the prefrontal cortex in the rapid antidepressant effects of ketamine . Am J Psychiatry . 2019 ; 176 : 388 – 400 .

8. Niciu , MJ , Ionescu , DF , Richards , EM , Zarate , CA. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder . J Neural Transm (Vienna) . 2014 ; 121 ( 8 ): 907 – 924 .

9. Freudenberg , F , Celikel , T , Reif , A. The role of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in depression: central mediators of pathophysiology and antidepressant activity? Neurosci Biobehav Rev . 2015 ; 52 : 193 – 206 .

10. Zarate , C , Machado-Vieira , R , Henter , I , et al . Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry . 2010 ; 18 ( 5 ): 293 – 303 .

11. Nguyen , L , Matsumoto , RR. Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice . Behav Brain Res . 2015 ; 295 : 26 – 34 .

12. Berman , FW , Murray , TF. Characterization of [3H]MK-801 binding to N-methyl-D-aspartate receptors in cultured rat cerebellar granule neurons and involvement in glutamate-mediated toxicity . J Biochem Toxicol . 1996 ; 11 ( 5 ): 217 – 226 .

13. Werling , LL , Keller , A , Frank , JG , Nuwayhid , SJ. A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder . Exp Neurol . 2007 ; 207 ( 2 ): 248 – 257 .

14. Robson , MJ , Elliott , M , Seminerio , MJ , Matsumoto , RR. Evaluation of sigma (σ) receptors in the antidepressant-like effects of ketamine in vitro and in vivo . Eur Neuropsychopharmacol . 2012 ; 22 ( 4 ): 308 – 317 .

15. Lauterbach , EC. An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan . Med Hypotheses . 2012 ; 78 ( 6 ): 693 – 702 .

16. Williams , NR , Heiferts , BD , Blasey , C , et al . Attenuation of antidepressant effects of ketamine by opioid receptor antagonism . Am J Psychiatry . 2018 ; 175 ( 12 ): 1205 – 1215 .

17. Wang , M and Kaplin , A. Explaining naltrexone’s interference with ketamine’s antidepressant effect . Am J Psychiatry . 2019 ; 176 ( 5 ): 410 –11.

18. Heiferts , BD , Williams , NR , Blasey , C , et al . Rigorous translational models are key to studying ketamine’s antidepressant mechanism: Response to Wang and Kaplin . Am J Psychiatry . 2019 ; 176 ( 5 ): 412 .

19. Gaginella , TS , Bertko , RJ , Kachur , JF. Effect of dextromethorphan and levomethorphan on gastric emptying and intestinal transit in the rat . J Pharmacol Exp Ther . 1987 ; 240 ( 2 ): 388 – 391 .

20. Kachur , JF , Morgan , DW , Gaginella , TS. Effect of dextromethorphan on guinea pig ileal contractility in vitro: comparison with levomethorphan, loperamide, and codeine . J Pharmacol Exp Ther . 1986 ; 239 ( 3 ): 661 – 667 .

21. National Institute of Mental Health . Major depression. NIMH website. 2019 . Accessed May 19, 2019. . Major depression. NIMH website. https://www.nimh.nih.gov/health/statistics/major-depression.shtml . Updated February. Accessed May 19, 2019.

22. World Health Organization . Fact sheets: depression. WHO website. 2018 . Accessed May 19, 2019. . Fact sheets: depression. WHO website. https://www.who.int/news-room/fact-sheets/detail/depression Published March 22,. Accessed May 19, 2019.

23. Rush , AJ , Trivedi , MH , Wisniewski , SR , et al . Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report . Am J Psychiatry . 2006 ; 163 ( 11 ): 1905 – 1917 .

24. Nierenberg , AA , Husain , MM , Trivedi , MH , et al . Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report . Psychol Med . 2010 ; 40 ( 1 ): 41 – 50 .

25. McClintock , SM , Husain , MM , Wisniewski , SR , et al . Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication . J Clin Psychopharmacol . 2011 ; 31 ( 2 ): 180 – 186 .

26. SYMBYAX® Prescribing Information . Indianapolis, IN: Lilly USA, LLC; March 2018 .

27. SPRAVATO™ Prescribing information . Titusville, NJ: Janssen Pharmaceuticals; May 2019 .

28. ABILIFY® Prescribing Information . Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd; February 2018 .

29. REXULTI® Prescribing Information . Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd; February 2018 .

30. Blier , P , Ward , HE , Tremblay , P , et al . Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study . Am J Psychiatry . 2010 ; 167 ( 3 ): 281 – 288 .